RBC Capital Maintains Sector Perform on CRISPR Therapeutics, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains a Sector Perform rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $66 to $60.
August 06, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on CRISPR Therapeutics but has lowered the price target from $66 to $60.
The lowered price target from $66 to $60 suggests a less optimistic outlook for CRISPR Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100